Literature DB >> 17326263

The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.

Alessandro Antonelli1, Alberto Cozzoli, Danilo Zani, Tiziano Zanotelli, Maria Nicolai, Sergio Cosciani Cunico, Claudio Simeone.   

Abstract

OBJECTIVE: To define a follow-up protocol based on the University of California Los Angeles Integrated Staging System (UISS) for patients undergoing surgery for N0M0 renal cell carcinoma (RCC). PATIENTS AND METHODS: The clinical records of patients treated with radical surgery for N0/NXM0 RCC and monitored through periodic follow-up studies (> or =24 months in disease-free patients) were reviewed retrospectively from 1399 patients surgically treated for renal neoplasms between 1983 and 2005. Each case was assigned a UISS risk category; recurrence features, time and site were recorded. In particular, recurrence sites were categorized into local, renal (ipsilateral or contralateral) and distant (single-site or disseminated).
RESULTS: The records were reviewed of 814 patients with a mean follow-up of 75.6 months. UISS risk categories were distributed as follows: high-risk (HR) 17.2%, intermediate-risk (IR) 51.6% and low-risk (LR) 31.2%. Disease-free survival rates at 5 years were 63.9%, 88.3% and 96.5% (log-rank test P < 0.001), respectively. The disease recurred in 193 patients (23.7%), at distant sites (73.0% of recurrences), locally (11.9%), in the contralateral kidney (10.9%) and in the ipsilateral kidney (4.1%). There was a significant correlation between UISS category and risk of distant or local (both P < 0.001) recurrences, whereas there was no correlation of recurrences in the operated kidney (P = 0.372) or contralateral kidney (P = 0.898).
CONCLUSIONS: The prognostic accuracy and applicability of the UISS for distant and local recurrences is confirmed, whereas renal relapses have an independent course. A follow-up scheme tailored to the recurrence patterns observed in each UISS risk group is recommended.

Entities:  

Mesh:

Year:  2007        PMID: 17326263     DOI: 10.1111/j.1464-410x.2006.06616.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients.

Authors:  Y A M Kuijpers; R P Meijer; G N Jonges; J de Jong; J L H R Bosch; S Horenblas; A Bex
Journal:  World J Urol       Date:  2016-04-07       Impact factor: 4.226

Review 2.  Post partial nephrectomy surveillance imaging: an evidence-based approach.

Authors:  Lorenzo Marconi; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

3.  Limited use of surveillance imaging following nephrectomy for renal cell carcinoma.

Authors:  Eric H Kim; Joel M Vetter; Adrienne N Kuxhausen; Joseph B Song; Gurdarshan S Sandhu; Seth A Strope
Journal:  Urol Oncol       Date:  2015-12-22       Impact factor: 3.498

4.  Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma.

Authors:  Tingting Wang; Yuhua Jiang; Lei Chu; Tianhui Wu; Jie You
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

5.  Hispidulin suppresses tumor growth and metastasis in renal cell carcinoma by modulating ceramide-sphingosine 1-phosphate rheostat.

Authors:  Ming-Quan Gao; Hui Gao; Mei Han; Kai-Li Liu; Jian-Jun Peng; Yan-Tao Han
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

6.  Hispidulin mediates apoptosis in human renal cell carcinoma by inducing ceramide accumulation.

Authors:  Hui Gao; Ming-Quan Gao; Jian-Jun Peng; Mei Han; Kai-Li Liu; Yan-Tao Han
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

Review 7.  Follow-up after curative treatment of localised renal cell carcinoma.

Authors:  Saeed Dabestani; Lorenzo Marconi; Teele Kuusk; Axel Bex
Journal:  World J Urol       Date:  2018-05-16       Impact factor: 4.226

Review 8.  Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma.

Authors:  Eric H Kim; Seth A Strope
Journal:  Urol Oncol       Date:  2015-09-26       Impact factor: 3.498

9.  Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.

Authors:  Nan E Rothrock; Sally E Jensen; Jennifer L Beaumont; Amy P Abernethy; Paul B Jacobsen; Karen Syrjala; David Cella
Journal:  Value Health       Date:  2013-06-19       Impact factor: 5.725

Review 10.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.